

## 1 **Supplemental Data**

2 New multi-target antagonists of  $\alpha_{1A}$ -,  $\alpha_{1D}$ -adrenoceptors and 5-HT<sub>1A</sub> receptors reduce  
3 human hyperplastic prostate cell growth and the increase of intraurethral pressure

4

5 Jéssica B Nascimento-Viana, Aline R Carvalho, Luiz Eurico Nasciutti, Rocío  
6 Alcántara-Hernández, Fernanda Chagas-Silva, Pedro A R Souza, Luiz Antônio S  
7 Romeiro, J Adolfo García-Sáinz, François Noël, and Claudia Lucia Martins Silva

8 Journal of Pharmacology and Experimental Therapeutics

9

## 10 **Supplemental Methods**

### 11 ***Binding assays: off-target BPH receptors***

12 In all cases, the assay volume was 0.5 ml and the radioligand depletion at the  
13 end of the experiments was less than 15% with the exception of the assays with [<sup>3</sup>H]-  
14 QNB in rat cortex preparation (around 40%) (Chagas-Silva et al., 2014).

15 For 5-HT<sub>2A</sub> receptor assays, 150 µg cortical membrane protein were incubated  
16 with LTDs ( $10^{-10}$  –  $10^{-4}$  M) in binding buffer containing 1 nM [<sup>3</sup>H]-ketanserin and 100  
17 nM prazosin, for 15 min at 37°C. Nonspecific binding was determined in the presence  
18 of 1 µM ketanserin.

19 For native  $\alpha_2$ -adrenoceptors, 150 µg cortical membrane protein were incubated  
20 with LTDs ( $10^{-8}$  –  $10^{-4}$  M) in binding buffer containing 1 nM [<sup>3</sup>H]RX821002, for 60 min  
21 at 30°C. Nonspecific binding was determined in the presence of 100 µM L-adrenaline  
22 bitartrate.

23 For native muscarinic receptors, 150 µg cortical membrane protein were  
24 incubated with 0.1 nM [<sup>3</sup>H]QNB, 50 mM Tris-HCl in the presence of LTDs ( $10^{-6}$  –  $10^{-3}$

25 M), at 25°C for 60 min. Atropine sulphate (10 µM) was used to determine non-specific  
26 binding (Chagas-Silva et al., 2014).

27

### 28 *Statistical analysis*

29

30 Otherwise indicated, data are expressed as means and SD. The significance of  
31 the differences among two or more conditions was determined by Student's *t* test or  
32 one-way analysis of variance (ANOVA) followed by *post hoc* Dunnett's test,  
33 respectively.

34

35

35 Supplemental Table 1. Affinity of LDT derivatives for native rat  $\alpha_2$ -adrenoceptors and  
 36 muscarinic receptors.

Compound (n)	$\alpha_2$ -adrenoceptors		muscarinic receptors	
	log IC <sub>50</sub> ± SD (M)	K <sub>i</sub> ( $\mu$ M)	log IC <sub>50</sub> ± SD (M)	K <sub>i</sub> ( $\mu$ M)
<b>LDT3</b> (4)	-5.97 ± 0.18	<b>0.93</b>	-4.26 ± 0.14	<b>56.7</b>
<b>LDT5</b> (3)	-6.53 ± 0.09**	<b>0.24</b>	-3.98 ± 0.10*	<b>108</b>
<b>LDT8</b> (4)	-6.22 ± 0.24	<b>0.55</b>	-4.48 ± 0.14	<b>34</b>
<b>LDT66<sup>a</sup></b> (3)	-5.92 ± 0.13 <sup>b</sup>	<b>0.81</b>	-3.80 ± 0.14	<b>52</b>
<b>yohimbine</b> (2)	-6.76 ± 0.07	<b>0.12</b>	---	---
<b>pirenzepine</b> (2)	---	---	-7.16 ± 0.04	<b>0.02</b>

37 IC<sub>50</sub> values (expressed as mean ± SD) were calculated by nonlinear regression of data  
 38 from binding competition assays using radiolabelled antagonists of  $\alpha_2$ -adrenoceptors  
 39 ([<sup>3</sup>H]RX-821002) and muscarinic receptors ([<sup>3</sup>H]-QNB). Yohimbine and pirenzepine  
 40 were used as positive controls for  $\alpha_2$ -adrenoceptor and muscarinic receptor antagonism,  
 41 respectively. K<sub>i</sub> values were calculated using the Cheng-Prusoff equation (Cheng and  
 42 Prusoff, 1973), considering K<sub>d</sub> values of 2.05 nM for [<sup>3</sup>H]RX-821002 (Chagas-Silva et  
 43 al., 2014) and 0.05 nM for [<sup>3</sup>H]-QNB (Luthin and Wolfe, 1984). Experiments were  
 44 performed in triplicates. <sup>a</sup> from Chagas-Silva et al., 2014 with permission; <sup>b</sup> n = 5.

45 F<sub>3,12</sub> = 9.347, P = 0.0018 for  $\alpha_2$ -adrenoceptors. \*\* P < 0.01 vs. LDT3 (one way ANOVA  
 46 followed by *post hoc* Dunnett's test)

47 F<sub>3,10</sub> = 17.56, P = 0.0003 for muscarinic receptors. \*P < 0.05 vs. LDT3 and LDT8 (one way  
 48 ANOVA followed by *post hoc* Dunnett's test)

49

50 Supplemental Table 2. Affinity and selectivity of LDTs towards native rat 5-HT  
 51 receptors.

Compound	5-HT <sub>1A</sub>	5-HT <sub>2A</sub>	Selectivity for 5-HT <sub>1A</sub> (5-HT <sub>2A</sub> /5-HT <sub>1A</sub> <i>K<sub>i</sub></i> ratio)
	<i>K<sub>i</sub></i> (M) (n)	<i>K<sub>i</sub></i> (M) (n)	
	[log IC <sub>50</sub> ± SD (M)]	[log IC <sub>50</sub> ± SD (M)]	
<b>LDT3</b>	<b>1.12 x 10<sup>-9</sup></b> (4) [-8.56 ± 0.07] ***	<b>7.08 x 10<sup>-8</sup></b> (3) [-7.15 ± 0.38] #	63
<b>LDT5</b>	<b>2.51 x 10<sup>-9</sup></b> (4) [-8.21 ± 0.05] ***	<b>3.89 x 10<sup>-7</sup></b> (3) [-6.41 ± 0.03] #	155
<b>LDT8</b>	<b>8.85 x 10<sup>-12</sup></b> (2) [-10.66 ± 0.03]	<b>3.89 x 10<sup>-7</sup></b> (3) [-6.41 ± 1.21] **	43,949
<b>LDT66<sup>a</sup></b>	<b>5.9 x 10<sup>-9</sup></b> (4) [-7.93 ± 0.40] ***	<b>1.78 x 10<sup>-6</sup></b> (3) [-5.57 ± 0.28] #	300

52 Data were obtained using binding competition assays with the radioligands [<sup>3</sup>H]-8-OH-  
 53 DPAT (5-HT<sub>1A</sub> receptor) and [<sup>3</sup>H]-ketanserin (5-HT<sub>2A</sub> receptor). *K<sub>i</sub>* values were  
 54 calculated using the Cheng-Prusoff equation (Cheng and Prusoff, 1973). Experiments  
 55 were performed in triplicates. <sup>a</sup> from Chagas-Silva et al., 2014 with permission.  
 56  $F_{3,10} = 72.18$ ,  $P < 0.0001$  for 5-HT<sub>1A</sub> receptors. \*\*\*  $P < 0.001$  compared to LDT 8 (one-  
 57 way ANOVA followed by a *post hoc* Dunnett's test). \*\*  $P < 0.01$ , #  $P < 0.001$  for 5-  
 58 HT<sub>2A</sub> versus 5-HT<sub>1A</sub> receptors (Student's *t* test).

59

60

61

62

63

64

65

66

67

68

69

70

71



72

73

74

75

76



77 Supplemental Figure 3. Inhibition of human hyperplastic prostate cell growth by LDT3  
78 and LDT5.

79 In these cells, proliferation (estimated by the MTT assay) induced by phenylephrine (A,  
80 PHE) or 5-HT (B) is mainly due to activation of  $\alpha_{1D}$ -adrenoceptors and 5-HT<sub>1A</sub>  
81 receptors, respectively. BMY 7378 and *p*-MPPF ( $\alpha_{1D}$ -adrenoceptors and 5-HT<sub>1A</sub>  
82 antagonists, respectively) were used as controls. Data are expressed as mean  $\pm$  SD of 5  
83 independent experiments performed in quintuplicates using three different cultures (see  
84 Methods).

85  $F_{7,32} = 7.558$ ,  $P < 0.0001$  for  $\alpha_{1D}$ -adrenoceptor.  $F_{7,32} = 5.221$ ,  $P = 0.0005$  for 5-HT<sub>1A</sub>  
86 receptor. \*\*\* $P < 0.001$  vs. agonist alone. One-way analysis of variance (ANOVA)  
87 followed by the *post hoc* Dunnett's test.

88


89

90

91

92

93




94

PHE 3.0 $\mu$ M	-	+	-	+	-	+	-	+	-	+
BMY7378 50 nM	-	-	+	+	-	-	-	-	-	-
LDT3 50 nM	-	-	-	-	+	+	-	-	-	-
LDT5 50 nM	-	-	-	-	-	-	+	+	-	-
LDT8 5 nM	-	-	-	-	-	-	-	-	+	+

95

96



100


5-HT 1.0 $\mu$ M	-	+	-	+	-	+	-	+	-	+
p-MPPF 50 nM	-	-	+	+	-	-	-	-	-	-
LDT3 50 nM	-	-	-	-	+	+	-	-	-	-
LDT5 50 nM	-	-	-	-	-	-	+	+	-	-
LDT8 5 nM	-	-	-	-	-	-	-	-	+	+

101

102 Supplemental Figure 4. Inhibition of the growth of human DU-145 prostate cancer  
 103 cells by LDT3, LDT5 and LDT8. Growth was estimated by MTT assay, and BMY  
 104 7378 (50 nM) and p-MPPF (50 nM) were used as selective antagonists of  $\alpha_{1D}$ -  
 105 adrenoceptors and 5-HT<sub>1A</sub> receptors, respectively. In these cells, proliferation  
 106 induced by phenylephrine (A, PHE) or 5-HT (B) is mainly due to activation of  $\alpha_{1D}$ -  
 107 adrenoceptors and 5-HT<sub>1A</sub> receptors, respectively. Data are expressed as mean  $\pm$  SD  
 108 of 3-4 independent experiments performed in triplicates.

109  $F_{9,61} = 8.002$ ,  $P < 0.0001$  for  $\alpha_{1D}$ -adrenoceptor.  $F_{9,61} = 5.394$ ,  $P < 0.0001$  for 5-HT<sub>1A</sub>  
 110 receptor. \* $P < 0.05$ , \*\* $P < 0.01$  and \*\*\* $P < 0.001$  compared to the agonists (one-way  
 111 ANOVA followed by the *post hoc* Dunnett's test).

112



Supplemental Figure 5. LDT3 and LDT5 inhibit the increase of intracellular  $Ca^{2+}$  in rat-1 cells transfected with  $\alpha_1$ -adrenoceptor subtypes. The increase of intracellular  $Ca^{2+}$   $[Ca^{2+}]_i$  was induced by 100  $\mu$ M phenylephrine. Antagonists were incubated for 100 sec before the addition of the agonist. Tamsulosin (n=3) and BMY7378 (n=3) were used as controls. LDT3 n=6 ( $\alpha_{1D}$ ), n=3 ( $\alpha_{1A}$ ,  $\alpha_{1B}$ ). LDT5 n=4 ( $\alpha_{1D}$ ), n=3 ( $\alpha_{1A}$ ,  $\alpha_{1B}$ ). Note that the error bars used here are the SEM (instead of SD) of the means.

157 **References**

158 Luthin GR, Wolfe BB (1984) [3H]Pirenzepine and [3H]quinuclidinyl benzilate binding  
159 to brain muscarinic cholinergic receptors. Differences in measured receptor density are  
160 not explained by differences in receptor isomerization. *Mol Pharmacol* **26**:164–169

161